Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. En savoir plus sur Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
[La Société Française du Cancer is moving forward]. En savoir plus sur [La Société Française du Cancer is moving forward].
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. En savoir plus sur BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. En savoir plus sur Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Éditorial de la Société Française du Cancer En savoir plus sur Éditorial de la Société Française du Cancer
[Innovative anticancer agents reserved to hospital use and not involved in the hospital budget: Creation and evolution]. En savoir plus sur [Innovative anticancer agents reserved to hospital use and not involved in the hospital budget: Creation and evolution].
[La Société française du cancer strengthens its information and education activity]. En savoir plus sur [La Société française du cancer strengthens its information and education activity].
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. En savoir plus sur Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.